525 
HR 2670 RDS
for housing calculated for such member under section 403 
of title 37, United States Code. 
(b) REPORT.—Not later than 180 days after the date 
of the enactment of this Act, the Secretary of Defense 
shall submit to the congressional defense committees a re-
port containing— 
(1) installation-specific data on the number of 
members of the Armed Forces and their dependents 
on military housing waitlists; 
(2) an identification of the time spent by each 
such member and their dependents awaiting appro-
priate housing accommodations; 
(3) an analysis of the factors that are creating 
the need for such waitlists; and 
(4) an assessment of the causes of waitlist du-
rations that exceed 10 days. 
SEC. 765. REPORT ON ACCESS OF TRICARE BENEFICIARIES 
TO NETWORK RETAIL PHARMACIES. 
(a) REPORT REQUIRED.—Not later than 180 days 
after the date of the enactment of this Act, the Secretary 
of Defense shall submit to Congress a report evaluating 
beneficiary access to TRICARE network pharmacies 
under the TPharm5 contract and changes in beneficiary 
access versus the TPharm4 contract. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00525
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
526 
HR 2670 RDS
(b) ELEMENTS.—The report required under sub-
section (a) shall include the following: 
(1) An analysis of pharmacy access in rural 
areas under such contracts, including: 
(A) The number of TRICARE bene-
ficiaries and number of TRICARE network re-
tail pharmacies located in rural areas. 
(B) The average drive time to the nearest 
TRICARE network retail pharmacy for a bene-
ficiary residing in rural areas. 
(C) The number of beneficiaries who live 
farther than a 15-minute drive to a TRICARE 
retail network pharmacy. 
(D) An assessment of medication compli-
ance rates for beneficiaries residing in rural 
areas for the three years prior to October 24, 
2022 compared to the period-to-date following 
October 24, 2022. 
(2) An analysis of TRICARE retail pharmacy 
network capabilities under such contracts, including 
the number of network pharmacies offering— 
(A) long-term care services; 
(B) prescription drug compounding serv-
ices; and 
(C) home infusion therapy services. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00526
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
527 
HR 2670 RDS
(3) An analysis of affected beneficiaries and 
their use of the TRICARE Pharmacy program 
under TPharm4 and TPharm5, including: 
(A) Data on affected beneficiaries’ use of 
MTF pharmacies, TRICARE mail order pro-
gram, Accredo, departed retail pharmacies, net-
work retail pharmacies. 
(B) An assessment of medication compli-
ance rates for affected beneficiaries for the 
three years prior to October 24, 2022 compared 
to the period-to-date following October 24, 
2022. 
(C) Data on affected beneficiaries’ use of 
pharmacies that offer long-term care services, 
compound pharmacies, home infusion therapy. 
(D) The number of affected beneficiaries 
and number of total TRICARE beneficiaries by 
age group: Under age 18, 18-24, 25-44, 45-64, 
65-79, 80 and older. 
(4) An analysis on the effect on long-term care 
residents under TPharm4 and TPharm5, including: 
(A) The number of beneficiaries who filled 
at least one prescription at a pharmacy that 
provides long-term care services. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00527
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
528 
HR 2670 RDS
(B) The number of beneficiaries who filled 
prescriptions at a single long-term care phar-
macy only with no prescriptions filled via mail 
order, MTF pharmacy, or another retail phar-
macy. 
(5) An analysis of non-network pharmacy use 
by TRICARE beneficiaries under TPharm4 and 
TPharm5, disaggregated by rural beneficiaries, non- 
rural beneficiaries, affected beneficiaries, rural af-
fected beneficiaries, and non-rural affected bene-
ficiaries: 
(A) The number of beneficiaries who used 
a non-network pharmacy. 
(B) The number of non-network claims 
submitted. 
(C) For all non-network claims sub-
mitted— 
(i) the average TRICARE allowed 
amount per prescription; 
(ii) the average TRICARE amount 
paid per prescription; and 
(iii) the verage beneficiary out-of- 
pocket cost per prescription. 
(h) DEFINITIONS.—In this section: 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00528
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
529 
HR 2670 RDS
(1) The term ‘‘affected beneficiary’’ means a 
beneficiary who filled at least one prescription in the 
year preceding October 24, 2022 at a departed phar-
macy. 
(2) The term ‘‘beneficiary’’ has the meaning 
given that term in section 1074g(i) of title 10, 
United States Code. 
(3) The term ‘‘departed retail pharmacy’’ 
means a retail pharmacy that participated in the 
TRICARE network in September, 2022 but left the 
network with the transition to the TPharm5 con-
tract. 
(4) The term ‘‘network pharmacy’’ means a re-
tail 
pharmacy 
described 
in 
section 
1074g(a)(2)(E)(ii) of title 10, United States Code. 
(5) The term ‘‘rural’’— 
(A) with regards to a location, has the 
meaning given such term in section 343(a) of 
the Consolidated Farm and Rural Development 
Act (7 U.S.C. 1991(a)); and 
(B) with regards to a beneficiary, has the 
meaning used by the Secretary of Defense in 
the administration of section 1074g of title 10, 
United States Code. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00529
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
530 
HR 2670 RDS
(6) The term ‘‘TPharm4’’ means the period 
covered by the 4th Generation pharmacy contract 
under TRICARE prior to October 24, 2022 when 
the retail network reduction went into effect. 
(7) The term ‘‘TPharm5’’ means the period 
covered by 5th Generation pharmacy contract under 
TRICARE to date. 
SEC. 766. STUDY AND REPORT ON FEASIBILITY OF LIFTING 
OUTPATIENT 
REHABILITATION 
THERAPY 
MAXIMUMS FOR CERTAIN MEMBERS OF THE 
ARMED FORCES WITH TRAUMATIC BRAIN IN-
JURY. 
(a) STUDY.—The Secretary of Defense shall conduct 
a study to analyze the feasibility of lifting outpatient reha-
bilitation therapy maximums for members of the Armed 
Forces who— 
(1) are serving on active duty and who 
(2) have suffered a brain injury while serving 
on active duty in the Armed Forces; and 
(3) are TRICARE beneficiaries. 
(b) ELEMENTS.—The study required by subsection 
(a) shall include the examination of a range of therapy 
services, including restorative therapies and therapies in-
tended to improve cognitive and functional capabilities. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00530
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
531 
HR 2670 RDS
(c) REPORT.—Not later than twelve months after the 
date of the enactment of this Act, the Secretary of Defense 
shall submit to Congress a report that includes the find-
ings and conclusions of the study required by subsection 
(a). 
SEC. 767. STUDY ON APPROVAL OF NON-GOVERNMENTAL 
ACCREDITATION BODIES FOR TRANSITIONAL 
AND RESIDENTIAL BRAIN INJURY TREAT-
MENT PROGRAMS. 
The Secretary of Defense shall conduct a study to 
analyze the feasibility of recognizing the approval of non- 
governmental accreditation bodies for transitional and res-
idential brain injury treatment programs for members of 
the Armed Forces who sustained a brain injury while serv-
ing on active duty in the Armed Forces. 
SEC. 768. STRATEGY TO SUSTAIN MEDICAL SUPPORT DUR-
ING OPERATIONS OF ARMED FORCES IN ARC-
TIC REGION. 
(a) STRATEGY.—Not later than May 3, 2024, the As-
sistant Secretary of Defense for Health Affairs, in coordi-
nation with the Surgeons General of the Armed Forces 
and the Joint Staff Surgeon, shall develop a strategy to 
sustain medical support during operations of the Armed 
Forces in the Arctic region, with a focus on addressing 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00531
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
533 
HR 2670 RDS
(c) BRIEFING.—Not later than 30 days after the date 
on which the Assistant Secretary of Defense for Health 
Affair completes the development of the strategy under 
subsection (a), the Assistant Secretary shall provide to the 
congressional defense committees a briefing on such strat-
egy. 
SEC. 769. STUDY ON USE OF ROUTINE NEUROIMAGING MO-
DALITIES IN DIAGNOSIS, TREATMENT, AND 
PREVENTION OF BRAIN INJURY DUE TO 
BLAST PRESSURE EXPOSURE DURING COM-
BAT AND TRAINING. 
(a) IN GENERAL.—The Secretary of Defense shall 
conduct a study on the feasibility and effectiveness of the 
use of routine neuroimaging modalities in the diagnosis, 
treatment, and prevention of brain injury among members 
of the Armed Forces due to one or more blast pressure 
exposures during combat and training. 
(b) REPORTS.— 
(1) INTERIM REPORT.—Not later than one year 
after the date of the enactment of this Act, the Sec-
retary shall submit to the Committees on Armed 
Services of the Senate and the House of Representa-
tives an interim report on the methods and action 
plan for the study under subsection (a). 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00533
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
534 
HR 2670 RDS
(2) FINAL REPORT.—Not later than two years 
after the date on which the Secretary begins the 
study under subsection (a), the Secretary shall sub-
mit to the Committees on Armed Services of the 
Senate and the House of Representatives a report on 
the results of such study. 
SEC. 770. PROHIBITION ON AVAILABILITY OF FUNDS FOR 
CLOSING AUSTIN’S PLAYROOMS AT CERTAIN 
MILITARY HOSPITALS. 
None of the funds authorized to be appropriated by 
this Act or otherwise made available for fiscal year 2024 
for the Department of Defense may be obligated or ex-
pended to close the Austin’s Playrooms at Naval Hospital 
Camp Pendleton, Naval Medical Center Camp Lejeune, or 
Naval Medical Center San Diego. 
SEC. 771. SENSE OF CONGRESS ON MAINTAINING IN-PA-
TIENT MILITARY MEDICAL TREATMENT FA-
CILITIES. 
It is the sense of the Congress that— 
(1) in-patient military Medical Treatment Fa-
cilities are critical components of the Military Health 
System and necessary to maintain a medically ready 
force that can be deployed at a moment’s notice on 
operational missions; 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00534
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
535 
HR 2670 RDS
(2) in-patient military Medical Treatment Fa-
cilities are required to develop the skilled medical 
force with the proper trained subspecialities needed 
to care for service members in wartime and during 
deployments; 
(3) each of the military departments should 
support a sufficient number of in-patient Medical 
Treatment Facilities to ensure military readiness; 
and 
(4) The Defense Health Agency and the mili-
tary departments, particularly the Department of 
the Air Force, should aggressively pursue creative 
options, including increased partnership with the 
Department of Veterans Affairs, to maintain eco-
nomical efficiency for the currently operating in-pa-
tient military Medical Treatment Facilities. 
SEC. 772. STUDY AND REPORT ON HEALTH CONDITIONS OF 
MEMBERS OF THE ARMED FORCES DEVEL-
OPED AFTER ADMINISTRATION OF COVID–19 
VACCINE. 
(a) STUDY.—The Secretary of Defense shall conduct 
a study to assess and evaluate any health conditions aris-
ing in members of the Armed Forces after one year after 
receiving the first dose of a COVID–19 vaccine, and each 
of the two years thereafter. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00535
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
536 
HR 2670 RDS
(b) STUDY PARAMETERS.—In conducting the study 
under subsection (a), the Secretary shall— 
(1) disaggregate data collected by— 
(A) vaccine type and manufacturer; 
(B) age group at the time such first dose 
was administered, including— 
(i) individuals who have attained 18 
years of age but who have not yet attained 
30 years of age; 
(ii) individuals who have attained 30 
years of age but who have not yet attained 
40 years of age; 
(iii) individuals who have attained 40 
years of age but who have not yet attained 
50 years of age; 
(iv) individuals who have attained 50 
years of age but who have not yet attained 
60 years of age; and 
(v) individuals who are 60 years of 
age or older; and 
(C) health condition developed after receiv-
ing such first dose, regardless of whether the 
condition is attributable to the receipt of such 
first dose; and 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00536
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
537 
HR 2670 RDS
(2) assess the prevalence of each such health 
condition— 
(A) by each age group specified in para-
graph (1)(B) among the unvaccinated popu-
lation; and 
(B) among each such age group for each 
of the years 2015, 2016, 2017, 2018, and 
2019. 
(c) REPORT.—Not later than one year after the date 
of the enactment of this Act and each year thereafter for 
the subsequent four years, the Secretary shall submit to 
the Committees on Armed Services of the House of Rep-
resentatives and the Senate a report on the results of each 
study conducted under subsection (a). 
(d) COVID–19 VACCINE
DEFINED.—The term 
‘‘COVID–19 vaccine’’ means a vaccine licensed under sec-
tion 351 of the Public Health Service Act (42 U.S.C. 262) 
or authorized for emergency use under section 564 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360bbb–3) for immunization against the virus responsible 
for COVID–19. 
SEC. 773. STUDY ON BLOOD WORK OF MEMBERS OF THE 
ARMED FORCES REGARDING COVID–19. 
(a) STUDY REQUIRED.—Not later than September 
30, 2024, the Secretary of Defense shall conduct a study 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00537
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
538 
HR 2670 RDS
to test the blood of members of the Armed Forces relating 
to relating to COVID–19. 
(b) ELEMENTS.—The study under this section shall 
include the following elements: 
(1) Testing to detect nucleocapsid protein 
immunoglobin-G antibodies relating to COVID–19. 
(2) Testing to detect T-cell immune response to 
COVID–19. 
(3) An assessment of the efficacy of each vac-
cine for COVID–19 in comparison to— 
(A) each other such vaccine; and 
(B) infection-acquired immunity. 
(4) An accounting of adverse events (including 
hyperimmune response), disaggregated by— 
(A) each vaccine described in paragraph 
(3); and 
(B) history of infection. 
(c) REPORT.—Not later than 180 days after com-
pleting the study, the Secretary shall submit a report on 
such study to the Committees on Armed Services of the 
Senate and House of Representatives. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00538
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
539 
HR 2670 RDS
TITLE VIII—ACQUISITION POL-
ICY, ACQUISITION MANAGE-
MENT, AND RELATED MAT-
TERS 
Subtitle A—Acquisition Policy and 
Management 
SEC. 801. COMMERCIAL NATURE DETERMINATION MEMO 
AVAILABLE TO CONTRACTOR. 
Section 3456(b)(2) of title 10, United States Code, 
is amended by adding at the end the following: ‘‘Upon the 
request of the contractor offering the product or service 
for which such determination is summarized in such 
memorandum, the contracting officer shall provide to such 
contractor a copy of such memorandum.’’. 
SEC. 802. PROHIBITION ON THE TRANSFER OF CERTAIN 
DATA ON EMPLOYEES OF THE DEPARTMENT 
OF DEFENSE TO THIRD PARTIES. 
(a) IN GENERAL.—Chapter 363 of title 10, United 
States Code, United States Code, is amended by adding 
at the end the following new section: 
‘‘§ 4662. Prohibition on the transfer of certain data on 
employees of the Department of Defense 
to third parties 
‘‘(a) IN GENERAL.—Each contract entered into by 
the Department of Defense on or after the date of the 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00539
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
540 
HR 2670 RDS
enactment of this section shall include a provision prohib-
iting the contractor and each subcontractor under such 
contract from selling, licensing, or otherwise transferring 
covered individually identifiable Department employee 
data to any individual or entity other than the Federal 
Government, except to the extent required to perform 
under such contract or a subcontract under such contract. 
‘‘(b) WAIVER.—The Secretary of Defense may waive 
subsection (a) with respect to a sale, licensing, or other 
transfer of covered individually identifiable Department 
employee data if the Secretary determines that such waiv-
er is appropriate. 
‘‘(c) DEFINITIONS.—In this section: 
‘‘(1) COVERED
INDIVIDUALLY
IDENTIFIABLE 
DEPARTMENT EMPLOYEE DATA.—The term ‘covered 
individually identifiable Department employee data’ 
means individually identifiable Department employee 
data obtained by— 
‘‘(A) a contractor pursuant to the perform-
ance of a contract described in subsection (a) 
by such contractor; or 
‘‘(B) a subcontractor pursuant to the per-
formance of a subcontract under such a con-
tract by such subcontractor. 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00540
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
541 
HR 2670 RDS
‘‘(2) INDIVIDUALLY
IDENTIFIABLE
DEPART-
MENT
EMPLOYEE
DATA.—The term ‘individually 
identifiable Department employee data’ means infor-
mation related to an employee of the Department of 
Defense, including a member of the armed forces, 
that— 
‘‘(A) identifies such employee; or 
‘‘(B) which may be used to infer, by either 
direct or indirect means, the identity of such an 
employee to whom the information applies.’’. 
(b) CLERICAL AMENDMENT.—The table of sections 
for chapter 363 of title 10, United States Code, is amend-
ed by adding at the end the following new item: 
‘‘4662. Prohibition on the transfer of certain data on employees of the Depart-
ment of Defense to third parties.’’. 
(c) REPORT ON COUNTERING IDENTIFYING INFOR-
MATION SPREAD.— 
(1) IN
GENERAL.—Not later than 180 days 
after the date of the enactment of this Act, the Sec-
retary of Defense shall submit to the congressional 
defense committees a report on the strategy of the 
Department of Defense to counter the proliferation 
of individually identifiable active duty member infor-
mation on commercially available datasets. 
(2) INDIVIDUALLY IDENTIFIABLE ACTIVE DUTY 
MEMBER
INFORMATION.—In this subsection, the 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00541
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
542 
HR 2670 RDS
term ‘‘individually identifiable active duty member 
information’’ means individually identifiable infor-
mation related to a member of the Armed Forces 
serving on active duty that— 
(A) identifies such member; or 
(B) which may be used to infer, by either 
direct or indirect means, the identity of such a 
member to whom the information applies. 
SEC. 803. PRINCIPAL TECHNOLOGY TRANSITION ADVISOR. 
(a) DESIGNATION.—Not later than one year after the 
date of the enactment of this Act, each Secretary of a mili-
tary department shall designate a Principal Transition 
Advisor who shall advise the Secretary on the transition 
of technologies, including technologies from science and 
technology programs of the Department, private commer-
cial entities, research institutions, and universities, to ful-
fill identified and potential warfighter requirements for 
the military department. 
(b) DIRECT REPORT.—The Principal Transition Ad-
visor of a military department designated under subsection 
(a) shall directly report to the Secretary of such military 
department. 
(c) RESPONSIBILITIES.—The Principal Transition 
Advisor of a military department designated under sub-
section (a) shall do the following: 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00542
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
543 
HR 2670 RDS
(1) Identify technologies being researched, de-
veloped, tested, or evaluated by science and tech-
nology programs of the Department, including De-
fense research facilities (as defined in section 
4125(b) of title 10, United States Code), that the 
military department may use to meet identified and 
potential warfighter requirements. 
(2) Consult with Department of Defense inno-
vation programs to identify technologies from private 
commercial entities, research institutions, univer-
sities, and other entities to identify technologies that 
the military department may use to meet identified 
and potential warfighter requirements. 
(3) Make recommendations to the Secretary of 
the military department regarding the acquisition of 
technologies identified under paragraphs (1) and 
(2), including recommendations on the programs of 
the military department under which the military de-
partment should make the acquisitions. 
(4) Inform program managers (as defined in 
section 1737 of title 10, United States Code) and 
other relevant acquisition officials of the military de-
partment of relevant technologies identified under 
paragraphs (1) and (2). 
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00543
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB
544 
HR 2670 RDS
(5) Develop and maintain metrics tracking the 
outcomes of projects and other activities of the mili-
tary department for which the military department 
expended amounts designated as budget activity 6 
(RDT&E management support) as that budget ac-
tivity classification is set forth in volume 2B, chap-
ter 5 of the Department of Defense Financial Man-
agement Regulation (DOD 7000.14-R). 
(d) CONGRESSIONAL REPORT.—Not later than one 
year after the designation of the Principal Transition Ad-
visor of a military department under subsection (a), and 
annually thereafter, the Principal Transition Advisor of 
such military department shall submit to Congress a re-
port on the following for the one-year period preceding the 
submission of the report: 
(1) The activities of the Principal Transition 
Advisor. 
(2) The outcomes of projects and other activi-
ties described in subsection (c)(5), including the 
metrics described in such subsection. 
(e) DEFINITIONS.—In this section: 
(1) DEPARTMENT.—The term ‘‘Department’’ 
means the Department of Defense. 
(2) DEPARTMENT
OF
DEFENSE
INNOVATION 
PROGRAMS.—The term ‘‘Department of Defense in-
VerDate Sep 11 2014 
05:13 Jul 28, 2023
Jkt 039200
PO 00000
Frm 00544
Fmt 6652
Sfmt 6201
E:\BILLS\H2670.RDS
H2670
pbinns on DSKJLVW7X2PROD with $$_JOB